BIIB vs IMUX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BIIB and IMUX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BIIB and IMUX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Biogen is a Cambridge, Massachusetts biotechnology company built on neuroscience. Its historic core is multiple sclerosis (Tysabri, Tecfidera, Vumerity), and it co-developed the spinal muscular atrophy drug Spinraza with Ionis. Its growth story now centers on Leqembi, the Alzheimer's antibody it markets with partner Eisai, alongside newer rare-disease products Skyclarys (Friedreich's ataxia) and Qalsody (ALS). In 2026 it closed the roughly $5.6 billion acquisition of Apellis Pharmaceuticals, adding the retinal drug Syfovre for geographic atrophy and Empaveli for rare blood and kidney diseases.

Full BIIB guide

Immunic, Inc. is a late-stage biotechnology company developing a portfolio of novel oral therapies aimed at neurologic and inflammatory diseases. Its lead program, vidofludimus calcium (IMU-838), is being tested in two large global Phase 3 trials, the ENSURE program, for relapsing multiple sclerosis, with thousands of patients enrolled and top-line data expected around the end of 2026. The drug is described as a first-in-class activator of the Nurr1 nuclear receptor, giving it a potential neuroprotective mechanism, combined with anti-inflammatory and anti-viral effects through selective inhibition of the DHODH enzyme.

Full IMUX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BIIB drivers: Leqembi Alzheimer's ramp; Rare-disease and new-product portfolio.
• IMUX drivers: Phase 3 multiple sclerosis readout; Differentiated mechanism.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars, and full-year 2026 total revenue is guided down a mid-single-digit percentage. For IMUX, the dominant risk is clinical trial failure: as a company whose value rests on vidofludimus calcium, a negative or ambiguous Phase 3 readout could cut the stock severely, since there is no approved product to fall back on.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BIIB if you believe its drivers more; IMUX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BIIB and IMUX guides.

BIIB. Biogen trades at a low double-digit forward earnings multiple, well below the drug-manufacturer industry median, reflecting a shrinking legacy base and turnaround uncertainty. Q1 2026 earnings beat expectations on cost discipline and Leqembi momentum, but management still guides full-year revenue down a mid-single-digit percentage. The valuation prices in doubt that new launches will outrun legacy erosion.

IMUX. Figures are approximate and tied to the asOf date; verify live numbers before acting. Traditional valuation metrics like P/E do not apply to a clinical-stage biotech with no earnings; the stock is valued on the probability-weighted potential of its pipeline, chiefly the Phase 3 multiple sclerosis readout, against its cash runway and share count. Value here is binary and event-driven, so the stock can move dramatically on a single data point. Treat any implied valuation as a bet on trial success, not on current fundamentals.

Headline figures (approximate, MAY 2026): BIIB shows revenue (ttm) ~$9.7B, q1 2026 revenue ~$2.5B (up ~2% YoY), q1 2026 non-gaap eps ~$3.57, market cap ~$29B; IMUX shows product revenue Essentially none; clinical-stage company with no approved products, lead program Vidofludimus calcium (IMU-838) in two Phase 3 relapsing-MS trials (ENSURE), key catalyst Top-line Phase 3 data expected around the end of 2026, cash position Boosted by a February 2026 private placement of roughly $187 million net; runway said to exceed twelve months.

BIIB and IMUX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BIIB and IMUX exposure against your real portfolio. It is not an investment adviser.